# The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Source: https://onco.cc/trials/nct05624138/  
OnCo record `nct05624138` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in colorectal cancer, run by Tanta University, now recruiting.

## Summary

The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy is a phase 3, randomised interventional study registered as NCT05624138 by Tanta University, with a registry enrolment figure of 64 participants, started 2022-11-09 and due to reach its primary completion in 2024-04-04. Interventions recorded: Placebo tablets; Ketotifen Oral Tablet. Conditions listed: Neuropathy;Peripheral. Primary outcome: variation in 12-item neurotoxicity questionnaire (Ntx-12) total score; variation in pain rating scale score; the percentage of patients with peripheral sensory neuropathy grade ≥ 2. Colorectal eligibility wording from the registry: "* Patients with histologically confirmed diagnosis of Stage III colorectal cancer". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05624138
- Phase: 3
- Setting: The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer
- Sponsor: Tanta University
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT05624138: https://clinicaltrials.gov/study/NCT05624138

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05624138.json